- Report
- July 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- May 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 383 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 214 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 179 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 289 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 193 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- February 2025
- 369 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2024
- 178 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2024
- 169 Pages
Global
From €2377EUR$2,500USD£1,997GBP

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more